Breaking News Instant updates and real-time market news.

BIIB

Biogen

$281.96

58.39 (26.12%)

06:09
10/23/19
10/23
06:09
10/23/19
06:09

Biogen upgraded to Buy from Neutral at Guggenheim

BIIB Biogen
$281.96

58.39 (26.12%)

10/22/19
OPCO
10/22/19
NO CHANGE
Target $334
OPCO
Outperform
Biogen price target raised to $334 from $280 at Oppenheimer
Oppenheimer analyst Jay Olson said Biogen offered detailed explanations regarding flaws in its previous futility analysis and how subsequent analysis of additional data revealed EMERGE as the first positive Phase 3 pivotal trial for a potentially Alzheimer's disease-modifying drug that could lead to regulatory approval. The analyst, who is optimistic about the prospects for aducanumab, restored the drug in his model with a 50% probability of success, leading him to increase his price target for Biogen shares to $334 from $280. Olson keeps an Outperform rating on Biogen.
10/22/19
STFL
10/22/19
NO CHANGE
Target $296
STFL
Hold
Biogen price target raise to $296 from $236 at Stifel
Stifel analyst Paul Matteis raised his price target for Biogen to $296 from $236 and maintained a Hold rating, reflecting a 33% probability of approval for aducanumab. In a research note to investors, Matteis says he attributes "legitimate credit" to Biogen for having already engaged the FDA in two meetings, but says "a battery of questions remains" regarding the aducanumab dataset that will go into the BLA. He views the EMERGE data as "clearly positive," but feels the ENGAGE data look "definitively negative," but is "unconfident" that the ENGAGE subgroup salvages the overall narrative.
10/22/19
PIPR
10/22/19
NO CHANGE
Target $305
PIPR
Neutral
Biogen price target raised to $305 from $250 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for Biogen to $305 from $250 after news that management intends to file for aducanumab approval. While investors "can rightly quibble with the chain of events that got us here," this is Alzheimer's and, "like a number of highly underserved disease states, FDA will likely exercise flexibility," Raymond tells investors in a research note. The analyst expects a filing in early 2020, FDA acceptance of the file and ultimately a panel committee "to keep hope alive" for aducanumab. Raymond, however, thinks handicapping the approval is "difficult at best." That said, "assuming a highly successful launch," aducanumab adds ~$70 to his sum-of-parts analysis. He remains on the sidelines with a Neutral rating on Biogen.
10/22/19
JEFF
10/22/19
NO CHANGE
Target $310
JEFF
Hold
Biogen price target raised to $310 from $255 at Jefferies
Jefferies analyst Michael Yee raised his price target for Biogen to $310 from $255 while keeping a Hold rating on the shares. The surprise announcement to file for Alzheimer's is good for investors, but will lead to another binary decision by the end of 2020 and "some time to wait," Yee tells investors in a research note. The analyst, however, likes the "call option" and believes the argument to FDA is "decent based on data," but cautions the agency "could easily ask for another study. Yee, who thinks Biogen doing acquisitions is now more likely, does not want to chase the shares on today's rally.

TODAY'S FREE FLY STORIES

CBWTF

Auxly Cannabis

$0.00

(0.00%)

07:33
11/22/19
11/22
07:33
11/22/19
07:33
Hot Stocks
Auxly says company 'ready to enter' Cannabis 2.0 market on first day of sales »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

, F

Ford

$8.72

-0.005 (-0.06%)

07:32
11/22/19
11/22
07:32
11/22/19
07:32
Recommendations
Tesla, Ford, General Motors analyst commentary  »

Tesla's $39,900…

TSLA

Tesla

F

Ford

$8.72

-0.005 (-0.06%)

GM

General Motors

$34.66

-0.6 (-1.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 09

    Dec

  • 04

    Feb

CTSH

Cognizant

$63.42

-0.09 (-0.14%)

07:32
11/22/19
11/22
07:32
11/22/19
07:32
Downgrade
Cognizant rating change  »

Cognizant downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMSY

HMS Holdings

$29.51

0.52 (1.79%)

07:32
11/22/19
11/22
07:32
11/22/19
07:32
Upgrade
HMS Holdings rating change  »

Guggenheim upgrades HMS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBWTF

Auxly Cannabis

$0.00

(0.00%)

07:31
11/22/19
11/22
07:31
11/22/19
07:31
Earnings
Auxly Cannabis reports Q3 EPS (C$0.03) vs. (C$0.02) last year »

Reports Q3 revenue C$1.6M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXE

Anixter

$85.30

-0.41 (-0.48%)

07:30
11/22/19
11/22
07:30
11/22/19
07:30
Hot Stocks
Anixter, CD&R announce amendment to up merger consideration to $82.50 per share »

As previously announced,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTSH

Cognizant

$63.42

-0.09 (-0.14%)

07:28
11/22/19
11/22
07:28
11/22/19
07:28
Downgrade
Cognizant rating change  »

Cognizant downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBS

Emergent BioSolutions

$52.46

-1.9 (-3.50%)

07:27
11/22/19
11/22
07:27
11/22/19
07:27
Recommendations
Emergent BioSolutions analyst commentary  »

Cantor reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$47.17

1.2 (2.61%)

07:27
11/22/19
11/22
07:27
11/22/19
07:27
Periodicals
Sanofi EVP in charge of strategy leaving by end of month, Reuters says »

Muzammil Mansuri,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

NXRT

NexPoint Residential

$47.61

-0.49 (-1.02%)

07:27
11/22/19
11/22
07:27
11/22/19
07:27
Initiation
NexPoint Residential initiated  »

NexPoint Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APLS

Apellis

$28.49

-0.15 (-0.52%)

07:26
11/22/19
11/22
07:26
11/22/19
07:26
Initiation
Apellis initiated  »

Apellis has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

KKR

KKR

$29.07

-0.25 (-0.85%)

07:26
11/22/19
11/22
07:26
11/22/19
07:26
Periodicals
KKR gets halfway in $3B Asia infrastructure fundraising, Reuters says »

According to Reuters, KKR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDHL

RedHill Biopharma

$5.70

-0.21 (-3.55%)

07:25
11/22/19
11/22
07:25
11/22/19
07:25
Conference/Events
RedHill Biopharma to host investor & analyst day »

Investor & Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

BXRX

Baudax Bio

$4.66

-0.59 (-11.24%)

07:24
11/22/19
11/22
07:24
11/22/19
07:24
Initiation
Baudax Bio initiated  »

Baudax Bio initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$53.89

1.41 (2.69%)

07:23
11/22/19
11/22
07:23
11/22/19
07:23
Initiation
Biohaven Pharmaceutical initiated  »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$56.84

0.455 (0.81%)

07:23
11/22/19
11/22
07:23
11/22/19
07:23
Initiation
Bristol-Myers initiated  »

Bristol-Myers resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

ENR

Energizer

$49.05

1.33 (2.79%)

07:22
11/22/19
11/22
07:22
11/22/19
07:22
Recommendations
Energizer analyst commentary  »

Energizer Analyst Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,734.99

-10.51 (-0.60%)

, MSFT

Microsoft

$149.46

-0.14 (-0.09%)

07:20
11/22/19
11/22
07:20
11/22/19
07:20
Periodicals
Amazon suit to likely delay start of Pentagon technology program, Bloomberg says »

Amazon (AMZN) could…

AMZN

Amazon.com

$1,734.99

-10.51 (-0.60%)

MSFT

Microsoft

$149.46

-0.14 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 04

    Dec

  • 09

    Dec

ABCB

Ameris Bancorp

$42.81

-0.4 (-0.93%)

07:19
11/22/19
11/22
07:19
11/22/19
07:19
Recommendations
Ameris Bancorp analyst commentary  »

Ameris Bancorp subpoena…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

BWEN

Broadwind Energy

$1.44

-0.06 (-4.00%)

07:18
11/22/19
11/22
07:18
11/22/19
07:18
Hot Stocks
Broadwind Energy receives first solar market order »

Broadwind Energy has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASTC

Astrotech

$1.51

-0.06 (-3.83%)

07:18
11/22/19
11/22
07:18
11/22/19
07:18
Hot Stocks
Astrotech says 1st Detect sells TRACER 1000s to shipping & logistics company »

Astrotech Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDGS

Medigus

$1.76

(0.00%)

07:17
11/22/19
11/22
07:17
11/22/19
07:17
Hot Stocks
Medigus receives $1.2M payment as part of MUSE agreement in China »

Medigus announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXLG

Destination XL

$1.45

-0.02 (-1.36%)

07:16
11/22/19
11/22
07:16
11/22/19
07:16
Hot Stocks
Breaking Hot Stocks news story on Destination XL »

Destination XL to close…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

T

AT&T

$37.59

0.415 (1.12%)

07:15
11/22/19
11/22
07:15
11/22/19
07:15
Recommendations
AT&T analyst commentary  »

AT&T near-term short…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 29

    Jan

DXLG

Destination XL

$1.45

-0.02 (-1.36%)

07:15
11/22/19
11/22
07:15
11/22/19
07:15
Hot Stocks
Destination XL expects FY19 free cash flow to be breakeven »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.